The Death of the Strategy of Classical Chiral Switches Is an Exaggeration

Israel Agranat; Ilaria D’Acquarica

doi:10.1021/acsmedchemlett.4c00450

The Death of the Strategy of Classical Chiral Switches Is an Exaggeration

Israel Agranat^*, Ilaria D’Acquarica^*

^*Corresponding author for this work

Institute of Chemistry

Research output: Contribution to journal › Review article › peer-review

Abstract

The strategy of classical chiral switches of drugs is still alive, contrary to a 2024 Journal of Medicinal Chemistry Perspective on approved chiral drugs claiming its death. Surveys of approved chiral-switch and racemic drugs should be based on reports of global regulatory authorities, not just FDA and EMA, which revealed overlooked chiral switches and racemates. The approved antihypertensive racemate nebivolol indicates the synergy between its enantiomers, highlighting the advocacy of developing racemic drugs.

Original language	English
Pages (from-to)	1797-1801
Number of pages	5
Journal	ACS Medicinal Chemistry Letters
Volume	15
Issue number	11
DOIs	https://doi.org/10.1021/acsmedchemlett.4c00450
State	Published - 14 Nov 2024

Bibliographical note

Publisher Copyright:
© 2024 American Chemical Society.

Keywords

chiral switch
global drug approvals
nebivolol
novel drugs
racemic drugs

Access to Document

10.1021/acsmedchemlett.4c00450

Cite this

@article{761f1ec0b10a4969be2059bab01adea9,

title = "The Death of the Strategy of Classical Chiral Switches Is an Exaggeration",

abstract = "The strategy of classical chiral switches of drugs is still alive, contrary to a 2024 Journal of Medicinal Chemistry Perspective on approved chiral drugs claiming its death. Surveys of approved chiral-switch and racemic drugs should be based on reports of global regulatory authorities, not just FDA and EMA, which revealed overlooked chiral switches and racemates. The approved antihypertensive racemate nebivolol indicates the synergy between its enantiomers, highlighting the advocacy of developing racemic drugs.",

keywords = "chiral switch, global drug approvals, nebivolol, novel drugs, racemic drugs",

author = "Israel Agranat and Ilaria D{\textquoteright}Acquarica",

note = "Publisher Copyright: {\textcopyright} 2024 American Chemical Society.",

year = "2024",

month = nov,

day = "14",

doi = "10.1021/acsmedchemlett.4c00450",

language = "אנגלית",

volume = "15",

pages = "1797--1801",

journal = "ACS Medicinal Chemistry Letters",

issn = "1948-5875",

publisher = "American Chemical Society",

number = "11",

}

TY - JOUR

T1 - The Death of the Strategy of Classical Chiral Switches Is an Exaggeration

AU - Agranat, Israel

AU - D’Acquarica, Ilaria

PY - 2024/11/14

Y1 - 2024/11/14

N2 - The strategy of classical chiral switches of drugs is still alive, contrary to a 2024 Journal of Medicinal Chemistry Perspective on approved chiral drugs claiming its death. Surveys of approved chiral-switch and racemic drugs should be based on reports of global regulatory authorities, not just FDA and EMA, which revealed overlooked chiral switches and racemates. The approved antihypertensive racemate nebivolol indicates the synergy between its enantiomers, highlighting the advocacy of developing racemic drugs.

AB - The strategy of classical chiral switches of drugs is still alive, contrary to a 2024 Journal of Medicinal Chemistry Perspective on approved chiral drugs claiming its death. Surveys of approved chiral-switch and racemic drugs should be based on reports of global regulatory authorities, not just FDA and EMA, which revealed overlooked chiral switches and racemates. The approved antihypertensive racemate nebivolol indicates the synergy between its enantiomers, highlighting the advocacy of developing racemic drugs.

KW - chiral switch

KW - global drug approvals

KW - nebivolol

KW - novel drugs

KW - racemic drugs

UR - http://www.scopus.com/inward/record.url?scp=85206432117&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.4c00450

DO - 10.1021/acsmedchemlett.4c00450

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 39563822

AN - SCOPUS:85206432117

SN - 1948-5875

VL - 15

SP - 1797

EP - 1801

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 11

ER -

The Death of the Strategy of Classical Chiral Switches Is an Exaggeration

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this